Skip to main content
. 2019 May 20;5:164–174. doi: 10.1016/j.trci.2019.04.001

Fig. 4.

Fig. 4

Estimated study powers to detect a treatment effect based on (A) randomized and (B) screened patients. Abbreviations: A+, amyloid positive; AD, Alzheimer's disease; ADAS-Cog, AD Assessment Scale–Cognitive subscale; APOE, apolipoprotein E; ε4+, APOE ε4 carrier; ε4++, APOE ε4 homozygous; ε4+−, APOE ε4 heterozygous; FH+, first-degree relative with AD; Optimal, optimal power curve (full 2-point treatment effect on the ADAS-Cog. no withdrawal); Phase 3, total phase 3 population.